TNYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenaya Therapeutics Inc (TNYA) is not a good buy for a beginner investor with a long-term strategy at this moment. Despite the recent positive news regarding a collaboration with Alnylam Pharmaceuticals, the stock's technical indicators suggest it is overbought, and insider selling is significantly high. Additionally, financial performance remains weak, with declining net income and EPS. Analysts have lowered price targets, and there are no strong proprietary trading signals to justify immediate action.
The MACD is positive and expanding, suggesting bullish momentum. However, the RSI is at 83.549, indicating the stock is overbought. Moving averages are converging, and the stock is trading near its resistance level of 0.908, which could limit further upside. Historical patterns suggest a high probability of price decline in the short term (-4.47% next day, -6.04% next week, -20.74% next month).
The company recently announced a collaboration with Alnylam Pharmaceuticals to validate up to 15 gene targets for heart disease, with potential milestone payments of $1.13 billion. This partnership could provide long-term growth opportunities.
Insiders are selling heavily, with a 55373.56% increase in selling activity over the last month. Financial performance remains weak, with declining net income (-20.91% YoY) and EPS (-60.00% YoY). Analysts have consistently lowered price targets, citing dilution and other concerns.
In Q3 2025, the company reported zero revenue growth (0% YoY). Net income dropped to -$20.28 million (-20.91% YoY), and EPS fell to -0.12 (-60.00% YoY). The financials indicate significant challenges in profitability and growth.
Analysts maintain Buy or Overweight ratings but have significantly lowered price targets recently. Morgan Stanley reduced the target to $2 from $5, Canaccord to $4 from $6, Chardan to $8 from $9, and H.C. Wainwright to $3 from $5. The reductions reflect concerns about dilution and financial performance.
